利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.024 秒)

    DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    4.
    发明公开
    DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION 审中-公开
    具有低BIOAKTIVIERUNGSPOTENTIAL二氟甲氧基CONNECTION减少β淀粉样蛋白的生产

    公开(公告)号：EP3126355A1

    公开(公告)日：2017-02-08

    申请号：EP15716671.1

    申请日：2015-04-01

    申请人： Bristol-Myers Squibb Company

    发明人： BOY, Kenneth M. ,  MERCER, Stephen E. ,  OLSON, Richard E. ,  ZHUO, Xiaoliang

    IPC分类号： C07D403/12 ,  A61K31/517 ,  A61P25/28 ,  A61P35/00

    CPC分类号： A61K31/517 ,  A61K2121/00 ,  C07D403/12

    摘要： The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.

    摘要翻译： 化合物N 2 - （3-（二氟甲氧基）-4-（3-甲基-1H-1,2,4-三唑-1-基）苯基）-7-（4-氟苯基）-N4,5,5三甲基 -6,7-二氢-5H-环戊二烯并[d]嘧啶-2,4-二胺：[请插入化学结构HERE]减少淀粉样肽（A 42）的生产，并且具有用于生物活化低电位，并且可以是在有用 治疗阿尔茨海默氏病的和受淀粉样肽（A 42）的生产的其他条件。

    CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
    5.
    发明授权
    CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS 有权
    具有减少构CGRP受体拮抗剂CONNECTIONS。

    公开(公告)号：EP2013213B1

    公开(公告)日：2011-07-27

    申请号：EP07761624.1

    申请日：2007-05-01

    申请人： Bristol-Myers Squibb Company

    发明人： MERCER, Stephen E. ,  CHATURVEDULA, Prasad V.

    IPC分类号： C07D491/04 ,  C07D487/04 ,  A61K31/55 ,  A61K31/553 ,  A61P25/06

    CPC分类号： C07D491/04 ,  C07D487/04

    摘要： The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Formula (I).

    CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
    7.
    发明公开
    CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS 有权
    具有减少构CGRP受体拮抗剂CONNECTIONS。

    公开(公告)号：EP2013213A2

    公开(公告)日：2009-01-14

    申请号：EP07761624.1

    申请日：2007-05-01

    申请人： Bristol-Myers Squibb Company

    发明人： MERCER, Stephen E. ,  CHATURVEDULA, Prasad V.

    IPC分类号： C07D487/04 ,  A61K31/55 ,  A61K31/553 ,  A61P25/06

    CPC分类号： C07D491/04 ,  C07D487/04

    摘要： The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Formula (I).